HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis
Status:
Completed
Trial end date:
2017-08-02
Target enrollment:
Participant gender:
Summary
Randomized, double blind study comparing the efficacy of pegylated interferon-alfa2a plus
placebo versus pegylated interferon-alfa2a plus tenofovir for the treatment of chronic delta
hepatitis. 70 Patients will be randomized 1:1 into the two groups. Treatment duration: 96
weeks. Follow-up: 24 weeks. Long-term-follow-up: until week 358.
Phase:
Phase 2
Details
Lead Sponsor:
HepNet Study House, German Liverfoundation
Collaborators:
Gilead Sciences Hannover Clinical Trial Center GmbH Hannover Medical School Hoffmann-La Roche